Rivaroxaban and Cognitive Decline: No Impact on Stroke or TIA in Young AF Patients

Rivaroxaban and Cognitive Decline: No Impact on Stroke or TIA in Young AF Patients

November 16, 2024 Catherine Williams - Chief Editor Health

BRAIN-AF Trial Findings

Table of Contents

The BRAIN-AF trial investigated the effects of rivaroxaban (Xarelto) on neurocognitive decline in adults under 65 years old diagnosed with atrial fibrillation (AF). The trial’s results revealed that taking rivaroxaban did not reduce the risk of cognitive decline, stroke, or transient ischemic attack (TIA).

Key Takeaways:

  • No Benefit of Anticoagulation: The trial showed that initiating oral anticoagulation (OAC) in younger adults with AF who do not have other cardiovascular risk factors does not provide benefits, contrary to the assumptions made for older patients with AF.

  • Trial Details: The BRAIN-AF trial aimed to enroll over 1,400 patients but was stopped early for futility, ultimately analyzing data from 1,235 participants.

  • Cognitive Decline Observed: Even though patients in the study had no prior strokes or TIA and low cardiovascular risks, 18% experienced a significant decline in cognitive function, as measured by the Montreal Cognitive Assessment (MoCA).

  • Cognitive Decline Mechanism: Dr. Léna Rivard noted that the trial results suggest a disconnect between anticoagulation and cognitive decline. While AF may still be linked with cognitive issues, anticoagulation does not appear to help.

Insights from Experts

Experts who discussed the trial emphasized the importance of understanding the mechanisms behind cognitive decline in patients with AF. They noted that addressing cognitive decline may be as crucial as preventing strokes. They recommended conducting additional studies to explore potential treatments that could mitigate cognitive decline in this patient population.

Conclusion

The BRAIN-AF trial raises critical questions about the relationship between AF, cognitive function, and the use of anticoagulation in younger patients. More research is needed to identify the reasons for cognitive decline in these patients and to explore potential interventions. In the meantime, maintaining a healthy lifestyle remains essential for individuals at risk for cognitive issues.